Guiding Personalized Treatment

Guiding Personalized Treatment

Advancing Personalized Medicine with Companion Diagnostics

What is Personalized Medicine?

Personalized medicine — also known as targeted medicine or precision medicine — is a rapidly-evolving area of healthcare in which the treatment for a medical condition such as cancer is tailored to the individual patient and his or her biology. There should not be a one-size-fits-all approach to medicine. The goal of personalized medicine is to prescribe the right medicine for the right patient at the right time.

What are Companion Diagnostics?

Companion diagnostics are medical tests that make personalized medicine possible. Designed to be paired with a specific drug , companion diagnostics help healthcare professionals determine which patients could be helped by that drug and which patients would not benefit, or could even be harmed.

Unlike other laboratory developed tests, companion diagnostics are reviewed and approved by the U.S. Food and Drug Administration (FDA), which is the gold standard for ensuring safety, effectiveness and quality. FDA approval gives physicians confidence they are receiving the highest quality test result on a consistent basis.

Myriad is a Pioneer in Companion Diagnostics

BRACAnalysis CDx companion diagnostic for ovarian cancer patients

BRACAnalysis CDx™ is an FDA-approved companion diagnostic that helps to identify women with advanced ovarian cancer with germline BRCA1/2 mutations who have completed three or more lines of chemotherapy and might benefit from treatment with Lynparza™ (olaparib).

myChoiceHRD companion diagnostic for cancer patients

Myriad myChoice® HRD is a tumor test that measures a cancer’s ability to repair DNA damage and may help identify more patients who may benefit from DNA-damaging chemotherapy agents.